NASDAQ · VNDA
Vanda Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for VNDA has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.44 | $-0.23 | $-0.57 | 3 |
| Mar 2027 | $-0.38 | $-0.35 | $-0.41 | 2 |
| Jun 2027 | $-0.23 | $-0.23 | $-0.24 | 2 |
| Sep 2027 | $-0.15 | $-0.11 | $-0.18 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Fintel · MarketBeat · Zacks- The Motley Fool · Oct 29, 1:44 AM EDTVanda (VNDA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Fintel · Oct 28, 8:22 PM EDTVanda Pharmaceuticals Inc. Reports Third Quarter 2026 Financial ResultsWASHINGTON – October 28, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026.Total net product sales were $69.8 million in Q3 2026, a 24% increase compared to $56.3 m
- MarketBeat · Oct 28, 8:04 PM EDTVanda Pharmaceuticals Q3 Earnings Call HighlightsVanda Pharmaceuticals (NASDAQ:VNDA) reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy purchasing and shipment timing. The company also said operat
- Zacks · Oct 28, 4:20 PM EDTVanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesVanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 28, 4:03 PM EDTVANDA PHARMACEUTICALS Q3 Loss Narrows(RTTNews) – VANDA PHARMACEUTICALS (VNDA) announced Loss for third quarter of -$22.562 million
- RTTNews · Oct 27, 7:13 AM EDTVanda Pharmaceuticals Announces Encouraging Data From NEREUS Phase 3 Study(RTTNews) – Tuesday, Vanda Pharmaceuticals Inc. (VNDA) announced positive results from Study 3601, evaluating NEREUS for the prevention of vomiting associated with GLP-1 receptor agonist therapy.
- Zacks · Oct 22, 9:00 AM EDTFortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 15, 12:05 PM EDTXENE's Depression Trial Setback: Is Its Pipeline Still Attractive?Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
- RTTNews · Sep 30, 12:05 AM EDTVanda Reports Positive Phase 3 Results For HETLIOZ In Delayed Sleep-Wake Phase Disorder; Stock Up(RTTNews) – Vanda Pharmaceuticals Inc. (VNDA) announced positive topline results from its pivotal Phase 3 study of HETLIOZ (tasimelteon) in adults with Delayed Sleep-Wake Phase Disorder, a circadian rhythm disorder that causes people to fall asleep and wake much later than desire
- RTTNews · Sep 29, 11:42 PM EDTVanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up(RTTNews) – Vanda Pharmaceuticals Inc. (VNDA) reported positive topline results from a Phase 3 study of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD).
- Fintel · Sep 23, 8:22 AM EDTOppenheimer Initiates Coverage of Vanda Pharmaceuticals with an Outperform RatingFintel reports that on September 23, 2026, Oppenheimer initiated coverage of Vanda Pharmaceuticals (NASDAQGM:VNDA) (DB:VM4) with a Outperform recommendation.Prior to this coverage initiation, the stock closed at $5.21 on September 22, 2026. This latest close represents a one-week
- RTTNews · Sep 9, 2:41 AM EDTPMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt Filing(RTTNews) – PMV Pharmaceuticals, Inc. (PMVP), a precision oncology company focused on p53-targeting therapies, announced appointment of Philip Herman as Chief Commercial Officer (CCO) to lead commercial strategy and launch preparations for Rezatapopt.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Vanda Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.